Business Wire

CA-LIGHTBITS-LABS

23.6.2020 15:02:08 CEST | Business Wire | Press release

Share
Lightbits Labs Launches LightOS® 2.0 with High Availability

Lightbits Labs , the originator and leader in NVMe™ over TCP (NVMe/TCP) software-defined block storage, today launched LightOS® 2.0, enabling full cloud-native persistent storage integration for Kubernetes with unprecedented scaling and availability via clustering.

With the efficiency and convenience of all-flash arrays and the high performance of direct-attached flash storage, LightOS 2.0 enables independent scaling of compute and storage. This solution maximizes Kubernetes functionality, provides ease of migration and delivers fast recovery times following server failure. LightOS 2.0 provides virtual NVMe volumes, delivering low latency and high performance, while at the same time providing high availability via seamless target-side storage server failover. The result is no interruption in service or forced migration due to a drive or storage node failure.

“Lightbits Labs is the only storage solution in production in the market today that allows data centers to take full advantage of NVMe/TCP,” said Lip-Bu Tan, Lightbits Board Member and Founding Managing Partner of WRVI Capital. “The advancements in LightOS 2.0 will ensure that customers can easily scale their infrastructure, and in-turn their business, without compromising performance, efficiency, or cost.”

LightOS 2.0 leverages a Container Storage Interface (CSI) plugin for Kubernetes to address the growing need for third-party storage support for stateful container storage needs. This has become more important as Kubernetes microservices move from stateless to stateful applications. LightOS 2.0 is ideal for containerized environments like Kubernetes that require large-scale clusters with persistent and durable storage for rapid node migration, workload rebalancing, or recovery from failure without copying data over the network. If any computer node in the network fails, data is moved virtually by pointing it to another container. Taken together, LightOS 2.0 allows for lower TCO via higher capacity utilization as well as increased operational efficiency via decreased downtime and infrastructure flexibility.

“At cloud scale, everything fails. LightOS 2.0 is the industry’s first NVMe/TCP scale-out clustered storage solution – protecting against data loss and avoiding service interruptions at scale in the presence of SSD, server, storage, or network failures,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs . “Now containerized applications can enjoy all of the benefits of disaggregated storage using LightOS CSI plugin for Kubernetes, spinning up persistent storage volumes for containerized workloads just as easily as spinning up another container.”

When installed on commodity servers in large-scale data centers, LightOS 2.0 is automatically optimized for I/O intensive compute clusters, such as Kafka, Cassandra, MySQL, MongoDB, and time series databases. Each storage server in the cluster can support up to 64K namespaces and 16K connections. With LightOS 2.0 providing a highly available and durable storage layer, application teams can focus their efforts on developing new services while LightOS 2.0 takes care of the underlying whole storage platform, guaranteeing the availability of and high-performance access to the data.

“It’s clear that customers want on-demand, high performance, always-available storage no matter where their workloads run. As applications move to the edge, we’re excited about the potential of Lightbits LightOS 2.0 to leverage our rich, interconnected datacenter fabrics, providing local flash-style performance without the operational and reliability issues of server installed drives.” – Zachary Smith, Managing Director for Bare Metal, Equinix

LightOS 2.0 provides the following benefits:

  • Software-defined disaggregated storage for cloud data centers delivering direct-attached NVMe SSD performance and up to a 50% reduction in tail latency
  • Optimized for low-cost QLC flash: Extends write endurance of drives and improves write performance without the need to modify applications
  • Fast container migration via CSI persistent and durable storage
  • Standards-based NVMe/TCP block storage access protocol for application-server-to-storage-server communication
  • LightOS clusters leverage standard NVMe-oF 1.1 multipathing with data protection on the storage target side, providing transparency to the client with fast failover
  • Distributed and durable cluster management with fast failover handling
  • No single point of failure in data and control paths
  • Multiple LightOS clusters can exist in the same cloud data center and clients can use multiple clusters simultaneously
  • Support for Kubernetes v1.13 and v1.15 - v1.18 and later for any volume size, number of volumes or Kubernetes size cluster
  • Rolling upgrades allow for LightOS updates without disruption to storage clients
  • Target-side solution that is easy to deploy at scale, without having to touch the network infrastructure or the clients
  • In cases where Kubernetes is integrated with the OpenStack platform, LightOS 2.0 allows for stateful containers through Kubernetes via CSI, or via a Cinder plugin

“LightOS 2.0 is game changing for the data center. It transforms a rack of x86 servers with NVMe drives into a large high-performance highly redundant storage pool connected to applications servers via NVMe/TCP with Kubernetes integration and high availability. Everything is standard in the solution – TCP protocol on Ethernet, network switches, NICs and drivers – without the need to consider specialized and costly new network infrastructure. Thus LightOS protects current investments and boosts deployments at no risk to deliver new SLA levels for modern application workloads. This is the perfect illustration of the Software-Defined Storage philosophy,” says Philippe Nicolas, Analyst Coldago Research.

To learn more about LightOS 2.0, join our upcoming webinar on June 30th at 10 a.m. PT, “Kubernetes Assimilation: Persistence is Futile .” Josh Goldenhar, VP of Product Marketing, will discuss how you can deploy high performance, low latency block storage in Kubernetes environments and get great performance, increased reliability and lower cost. Register now to save your seat.

Lightbits Labs Resources

About Lightbits Labs™

Lightbits Labs, founded in 2016, is a software-defined storage company that brings hyperscale efficiency and flexibility to everyone. Lightbits’ solution delivers composable, disaggregated NVMe/TCP software-defined storage that performs like local Flash. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that from applications’ perspective is indistinguishable from local SSDs. Lightbits Labs is backed by strategic investors including Dell Technologies Capital, Cisco Investments and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye